Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Sep 1;106(9):2417-2426.
doi: 10.3324/haematol.2020.275958.

Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

Johannes Duell  1 , Kami J Maddocks  2 , Eva González-Barca  3 , Wojciech Jurczak  4 , Anna Marina Liberati  5 , Sven De Vos  6 , Zsolt Nagy  7 , Aleš Obr  8 , Gianluca Gaidano  9 , Pau Abrisqueta  10 , Nagesh Kalakonda  11 , Marc André  12 , Martin Dreyling  13 , Tobias Menne  14 , Olivier Tournilhac  15 , Marinela Augustin  16 , Andreas Rosenwald  17 , Maren Dirnberger-Hertweck  18 , Johannes Weirather  18 , Sumeet Ambarkhane  18 , Gilles Salles  19
Affiliations
Clinical Trial

Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

Johannes Duell et al. Haematologica. .

Abstract

Tafasitamab (MOR208), an Fc-modified, humanized, anti-CD19 monoclonal antibody, combined with the immunomodulatory drug lenalidomide was clinically active with a good tolerability profile in the open-label, single-arm, phase II L-MIND study of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem-cell transplantation. To assess long-term outcomes, we report an updated analysis with ≥35 months' follow-up. Patients were aged >18 years, had received one to three prior systemic therapies (including ≥1 CD20-targeting regimen) and Eastern Cooperative Oncology Group performance status 0-2. Patients received 28-day cycles of tafasitamab (12 mg/kg intravenously), once weekly during cycles 1-3, then every 2 weeks during cycles 4-12. Lenalidomide (25 mg orally) was administered on days 1-21 of cycles 1-12. After cycle 12, progression-free patients received tafasitamab every 2 weeks until disease progression. The primary endpoint was best objective response rate. After ≥35 months' follow-up (data cut-off: October 30, 2020), the objective response rate was 57.5% (n=46/80), including a complete response in 40.0% of patients (n=32/80) and a partial response in 17.5% of patients (n=14/80). The median duration of response was 43.9 months (95% confidence interval [95% CI]: 26.1-not reached), the median overall survival was 33.5 months (95% CI: 18.3-not reached) and the median progression-free survival was 11.6 months (95% CI: 6.3-45.7). There were no unexpected toxicities. Subgroup analyses revealed consistent long-term efficacy results across most subgroups of patients. This extended follow-up of L-MIND confirms the long duration of response, meaningful overall survival, and well-defined safety profile of tafasitamab plus lenalidomide followed by tafasitamab monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma ineligible for autologous stem cell transplantation. ClinicalTrials.gov identifier: NCT02399085.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
CONSORT (Consolidated Standards of Reporting Trials) diagram of the L-MIND study at the October 30, 2020 data cut-off.
Figure 2.
Figure 2.
Proportion of patients in remission. (A-C) Kaplan-Meier plots of duration of response (A), progression-free survival. (B) and overall survival (C) after 35 months of follow-up. 95% CI. 95% confidence interval; CR: complete response; DoR: duration of response; NE: not evaluable; NR: not reached; OS: overall survival; PD: progressive disease; PFS: progression- free survival; PR: partial response; SD: stable disease.
Figure 3.
Figure 3.
Kaplan-Meier estimates of 30-month time-toevent endpoints. (A) Duration of response,* (B) progression-free survival and (C) overall survival rates. *Based on patients who achieved an objective response (CR or PR) in the respective subgroups. 95% CI: 95% confidence interval; DoR: duration of response; IPI: International Prognostic Index; nC: number of patients censored; nE: number of patients with event; nR: number of patients at risk; n#: number of responders within each subgroup (A: DoR), or number of overall patients within each subcategory (B: PFS; C: OS); OS: overall survival; PFS: progression- free survival. The vertical line indicates the 30- month DoR (A), PFS (B) and OS (C) rates across all responders/patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization. World Cancer Report 2020: Cancer Research for Cancer Prevention. Cancer Control. 2020;199.
    1. Sarkozy C, Sehn LH. New drugs for the management of relapsed or refractory diffuse large B-cell lymphoma. Ann Lymphoma. 2019;3:10.
    1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines: B-Cell Lymphomas V3.2021. Published 2021. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed February 7, 2021.
    1. Tilly H, Gomes da Silva M, Vitolo U, et al. . Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116-v125. - PubMed
    1. Neelapu SS, Locke FL, Bartlett NL, et al. . Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544. - PMC - PubMed

Publication types

MeSH terms

Associated data